Nuwellis Inc vs Global X Uranium ETF — how do they compare? Nuwellis Inc trades at $0.79 (market cap $2.54M), while Global X Uranium ETF trades at $46.45. The key difference: Global X Uranium ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | URA | |
|---|---|---|
Market Cap | $2.54M | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $164.50 | $61.81 |
52-Week Low | $0.73 | $37.52 |
Enterprise Value | -$1.17M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
URA (Global X Uranium ETF) trades at $47.50, up 3.13% today, with strong bullish technical signals from moving averages. The ETF benefits from growing nuclear energy demand driven by AI power needs and government support, including recent $17.5 billion in U.S. reactor funding. However, key financial ratios remain unavailable, and the sector faces volatility from uranium price fluctuations and regulatory shifts.
Outlook remains positive due to structural tailwinds in nuclear energy, but investors should monitor uranium contract pricing and ETF expense ratios. Near-term resistance sits at $48-$50, with support at $45-$47. Risks include policy changes and miner concentration, though institutional interest in nuclear ETFs is rising.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →